1.Experimental study on effects of emodin on nonalcoholic fatty liver induced by high fat diet in rats.
Hui DONG ; Fu-er LU ; Zhi-qiang GAO
Chinese Journal of Integrated Traditional and Western Medicine 2006;26 Suppl():64-67
OBJECTIVETo investigate the therapeutic effect of emodin on nonalcoholic fatty liver (NAFL) induced by high fat diet in rats.
METHODSNAFL model was established by feeding with high fat diet for 12 weeks in 40 SD rats, confirmed by liver pathologic examination, which were randomly divided into 5 groups: the model control group the mere dietary treatment group (both with distilled water by gastrgarege), the low, moderate and high dose emodin groups treated with emodin 20,40 and 80 mg x kg(-1) x d(-1) once per day respectively. Meanwhile a normal control group was used. The model control group was still fed with high fat diet while the other groups with normal diet. After 4 weeks, body weight, liver index (liver weight/body weight), hepatic function, blood lipid, hepatic lipid and histologic changes were assayed.
RESULTSIn the model control group,body weight, liver index, hepatic enzyme activities, serum lipid and hepatic triglyceride increased significantly (P <0. 05, or P <0. 01), serum high density lipoprotein-cholesterol( HDL-C)decreased (P <0.01 ), and moderate to severe hepatocyte steatosis was observed, while these indexes were all improved significantly in the 3 emodin groups; hepatic histologic changes were improved in the mere dietary treatment group, however, high level of ALT and hyperlipidemia persisted.
CONCLUSIONEmodin combined with dietary therapy is effective for NAFL rats induced by high fat diet.
Animals ; Cholesterol, HDL ; blood ; Dietary Fats ; toxicity ; Drugs, Chinese Herbal ; therapeutic use ; Emodin ; therapeutic use ; Fatty Liver ; diet therapy ; drug therapy ; etiology ; Rats ; Rats, Sprague-Dawley
2.In vivo tracing of transferred apoptotic cell labeled using CFSE: a flow cytometry-based assay method.
Yan WANG ; Yi GAO ; Er-wei SUN ; Jin-min XIE ; Hui-ying ZHANG ; Jian-bo CHEN
Journal of Southern Medical University 2006;26(5):599-602
OBJECTIVETo establish an assay method for detecting the migration of transferred apoptotic cells into the recipient using flow cytometry.
METHODSSpleen lymphocytes were isolated and labeled with an intracellular amine dye, carboxyfluorescein diacetate succinimidyl ester (CFSE), to allow discrimination. The labeled cells were induced with dexamethasone to undergo apoptosis and transferred into recipient mice via tail venous transfusion. Flow cytometry and histological examination of different tissues were performed at different time points. The stability of CFSE labeling for apoptotic cells was also tested.
RESULTSThe CFSE-labeled apoptotic cells were highly fluorescent with a positive labeling rate of (98.0+/-1.9)%. The stability of CFSE-labeling was testified, and the CFSE-labeled apoptotic cells entering different tissues at different time points were detected by flow cytometry and verified by histological examination.
CONCLUSIONFlow cytometry using CFSE labeling is reliable, sensitive, precise and convenient for apoptotic cell tracing in vivo and in vitro.
Adoptive Transfer ; methods ; Animals ; Apoptosis ; Dexamethasone ; pharmacology ; Female ; Flow Cytometry ; methods ; Fluoresceins ; chemistry ; pharmacokinetics ; Fluorescent Dyes ; chemistry ; pharmacokinetics ; Lymphocytes ; chemistry ; cytology ; drug effects ; Mice ; Mice, Inbred BALB C ; Reproducibility of Results ; Spleen ; cytology ; Succinimides ; chemistry ; pharmacokinetics
3.Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding.
Zhi-Qiang GAO ; Fu-Er LU ; Hui DONG ; Li-Jun XU ; Kai-Fu WANG ; Xin ZHOU
Chinese Journal of Hepatology 2005;13(2):101-104
OBJECTIVESTo explore the therapeutic effects of metformin on rat fatty livers induced by high fat feeding.
METHODSA fatty liver model was established by feeding rats with a high caloric laboratory chow for 12 weeks, then the rats were randomly divided into three groups, i.e. model control group, metformin group and dietary treatment group. A normal control group was organized at the same time. The rats of the metformin group were given metformin 156 mg/kg/d while the other groups were given distilled water of the same volume by stomach feeding. The model control group rats were fed with high caloric laboratory chow while other groups were fed a normal diet. After four weeks, all the animals were sacrificed. Liver index (liver/body weight ratio), serum activities of liver-associated enzymes, blood lipids, liver triglycerides, fasting blood glucose, fasting plasma insulin, HOMA insulin resistance index (HOMA-IR), and the liver histology of rats of all groups were assayed.
RESULTSThe body weight, liver index, serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total cholesterol (TC), triglycerides (TG) and liver triglycerides in the model group increased significantly, while HDL-cholesterol concentration decreased significantly. Fasting blood glucose, fasting plasma insulin and HOMA-IR showed an increasing tendency, but there was no significant difference of those indexes among the three groups. The liver histology in the model group showed moderate to severe steatosis, mainly as macro vesicle steatosis, lobular inflammatory, cell infiltration and necrosis. Compared with the model group, the levels of body weight, liver index, serum ALT, ALP, TC, TG and liver triglycerides in the metformin group were significantly lower and were similar to those of the normal group, while their HDL-cholesterol concentration was significantly higher. The liver histology in the metformin group was nearly normal. In the dietary treatment group, hyperlipidemia persisted, although liver index and GGT were lower and the liver histology changes were somewhat milder.
CONCLUSIONIt is suggestive that metformin might be effective in treating rat fatty liver induced by high fat feeding.
Animals ; Dietary Fats ; administration & dosage ; Fatty Liver ; drug therapy ; etiology ; Hypoglycemic Agents ; therapeutic use ; Male ; Metformin ; therapeutic use ; Random Allocation ; Rats ; Rats, Sprague-Dawley
4.Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes.
Zhong-Qing YAN ; San-Hua LENG ; Fu-Er LU ; Xiao-Hong LU ; Hui DONG ; Zhi-Qiang GAO
China Journal of Chinese Materia Medica 2008;33(18):2105-2109
OBJECTIVETo observe the expression of hepatocyte nuclear factor 4alpha (HNF4alpha) and the activity of key enzyme glucokinase (GK) in glucose metabolism, and further to investigate the possible mechanism of berberine in treating type 2 diabetes.
METHODMouse primary hepatocytes were isolated by an improved single two-step perfusion method. The murine hepatocytes were cultured and incubated with berberine (0, 1, 3, 10, 30, 100 micromol x L(-1)) and 1 mmol x L(-1) metformin for 24 h respectively. The mRNA expression of HNF4alpha were quantified by RT-PCR and the protein expression of HNF4alpha were quantified by Western-blot. And the activity of GK were detected with enzyme kinetics method.
RESULTAs compared with the negative control group, at a certain concentration range, the expression of HNF4alpha mRNA and protein and the activity of GK were promoted by berberine. Both of them reached the top at the concentration of 30 micromol x L(-1) (P<0.01). But the metformin made no difference with the negative control group on the expression of HNF4alpha and the activity of GK.
CONCLUSIONIt is suggested that the effects of berberine on improving glucose metabolism can be mechanically associated with its up-regulating the HNF4a expression and inducing the activity of hepatic glucokinase.
Animals ; Berberine ; pharmacology ; Cell Survival ; drug effects ; Cells, Cultured ; Gene Expression Regulation ; drug effects ; Glucokinase ; genetics ; metabolism ; Hepatocyte Nuclear Factor 4 ; genetics ; metabolism ; Hepatocytes ; cytology ; drug effects ; metabolism ; Male ; Mice ; Plant Extracts ; pharmacology
5.The Stent-Assisted Coil-Jailing Technique Facilitates Efficient Embolization of Tiny Cerebral Aneurysms.
Cong Hui LI ; Xian Hui SU ; Bo ZHANG ; Yong Feng HAN ; Er Wei ZHANG ; Lei YANG ; Dong Liang ZHANG ; Song Tao YANG ; Zhen Quan YAN ; Bu Lang GAO
Korean Journal of Radiology 2014;15(6):850-857
OBJECTIVE: Tiny cerebral aneurysms are difficult to embolize because the aneurysm's sac is too small for a single small coil, and coils within the aneurysm may escape from the confinement of a stent. This study was performed to introduce the stent-assisted coil-jailing technique and to investigate its effect on the coil embolization of tiny intracranial aneurysms. MATERIALS AND METHODS: Sixteen patients with tiny intracranial aneurysms treated with the stent-assisted coil-jailing technique between January 2011 and December 2013 were retrospectively reviewed and followed-up. RESULTS: All aneurysms were successfully treated with the coil-jailing technique, and at the end of embolization, complete occlusion of the aneurysm was achieved in 9 cases (56.3%), incomplete occlusion in 6 (37.5%), and partial occlusion in 1 (6.3%). Intraprocedural complications included acute thrombosis in one case (6.3%) and re-rupture in another (6.3%). Both complications were managed appropriately with no sequela. Follow-up was performed in all patients for 3-24 months (mean, 7.7 months) after embolization. Complete occlusion was sustained in the 9 aneurysms with initial complete occlusion, progressive thrombosis to complete occlusion occurred in the 6 aneurysms with initial near-complete occlusion, and one aneurysm resulted in progressive thrombosis to complete occlusion after initial partial occlusion. No migration of stents or coils occurred at follow-up as compared with their positions immediately after embolization. At follow-up, all patients had recovered with no sequela. CONCLUSION: The stent-assisted coil-jailing technique can be an efficient approach for tiny intracranial aneurysms, even though no definite conclusion regarding its safety can be drawn from the current data.
Adult
;
Aged
;
Cerebral Angiography
;
Embolization, Therapeutic/*instrumentation
;
Female
;
Follow-Up Studies
;
Humans
;
Intracranial Aneurysm/pathology/*therapy
;
Magnetic Resonance Angiography
;
Male
;
Middle Aged
;
Retrospective Studies
;
Severity of Illness Index
;
Stents
;
Treatment Outcome
6.Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma.
Yi-ran ZHAO ; Rong FU ; Jing GUAN ; Shan GAO ; Hui LIU ; Er-bao RUAN ; Wen QU ; Yong LIANG ; Guo-jin WANG ; Xiao-ming WANG ; Hong LIU ; Yu-hong WU ; Jia SONG ; Hua-quan WANG ; Li-min XING ; Jun WANG ; Li-juan LI ; Zong-hong SHAO
Chinese Journal of Hematology 2012;33(4):274-277
OBJECTIVETo investigate the expression of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma (MM), and explore the importance of Notch signaling pathway in the formation and progression of MM.
METHODSThirty three MM patients and 15 healthy controls were enrolled in this study. The expression of Notch1 on the membrane of bone marrow CD38(+)CD138(+) and CD38(+)CD138(-) plasma cells were analyzed by flow cytometry. The clinical data of MM patients were also analyzed.
RESULTSThe ratio of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients was (60.21 ± 25.06)% which was significantly higher than those of CD38(+)CD138(-) plasma cells of MM patients (39.84 ± 18.94)% (P = 0.000) and controls (38.34 ± 19.39)% (P = 0.004). There was no statistical difference between the two latter groups (P > 0.05). The expression of Notch1 on CD38(+)CD138(+)plasma cells from 24 newly diagnosed MM patients was correlated to the level of malignant plasma cells in there bone marrow (r = 0.914, P = 0.000), serum level of lactate dehydrogenase (LDH) (r = 0.754, P = 0.007), and β(2)-MG(r = 0.716, P = 0.013). The ratio of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients who had renal dysfunction was correlated to their abnormal serum creatinine levels. The expression of Notch1 on CD38(+)CD138(+) plasma cells from 17 MM patients who received VD (bortezamib and dexamethasone) chemotherapy was correlated to the ratio of plasma cell reduction after the first VD chemotherapy (r = 0.842, P = 0.000).
CONCLUSIONThe expression of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients was significantly higher than those of CD38(+)CD138(-) plasma cells of MM patients and controls. Notch1 overexpressed plasma cells were sensitive to the early VD therapy, and correlated to the progression and long term outcome of MM.
ADP-ribosyl Cyclase 1 ; immunology ; Adult ; Aged ; Aged, 80 and over ; Bone Marrow ; metabolism ; Case-Control Studies ; Cell Count ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma ; immunology ; metabolism ; Plasma Cells ; immunology ; metabolism ; Prognosis ; Receptor, Notch1 ; metabolism ; Syndecan-1 ; immunology
7.Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia.
Chun-Yan LIU ; Rong FU ; Wen-Hui LIU ; Yu-Qian CHENG ; Wen-Xiu SONG ; Li-Juan DU ; Er-Bao RUAN ; Li-Tong ZHANG ; Xiao-Ming WANG ; Yong LIANG ; Guo-Jin WANG ; Wen QU ; Jia SONG ; Rong-Li ZHANG ; Jing GUAN ; Li-Juan LI ; Yang SONG ; Shan GAO ; Hui LIU ; Hui-Juan JIANG ; Jun WANG ; Peng ZOU ; Zong-Hong SHAO
Journal of Experimental Hematology 2007;15(6):1300-1304
To analyze the prognosis and risk factors of acute nonlymphocytic leukemia (ANLL), 94 patients with acute nonlymphocytic leukemia were enrolled in this study, while survival rate and risk factors of prognosis were analyzed. The results indicated that the complete remission (CR) ratio was 51.1%. Overall survival and event-free survival rates of month 6, 12, 18, 24 were 68.6%, 55.8%, 53.8%, 46.4%, 21.3% and 57.9%, 38.6%, 33.3%, 31.6%, 0% respectively. The factors such as age<40 years, WBC<10.0x10(9)/L before chemotherapy, WBC in the period of bone marrow suppression<1.0x10(9)/L, chemotherapy within 1 month after occurrence of leukemia, blood transfusion before chemotherapy of APL had favourable influence on remission and survival rates of ANLL patients. CR1, the time to get CR, length of CR and relapse significantly correlated with prognosis (p<0.05). It is concluded that the individualized therapy concerning the risk factors should be applied to ANLL patients for improving the remission, survival rate and prognosis.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Cytarabine
;
administration & dosage
;
therapeutic use
;
Female
;
Harringtonines
;
administration & dosage
;
therapeutic use
;
Humans
;
Leukemia, Myeloid, Acute
;
diagnosis
;
drug therapy
;
Male
;
Middle Aged
;
Prognosis
;
Tretinoin
;
administration & dosage
;
therapeutic use
;
Young Adult
8.Recent research advances of 1-deoxynojirimycin and its derivatives.
Ting-Ting TONG ; Er-Hu ZHAO ; Hai-Long GAO ; Yong-Hui XU ; Yong-Ju ZHAO ; Gang FU ; Hong-Juan CUI
China Journal of Chinese Materia Medica 2018;43(10):1990-1997
The 1-DNJ named 1-deoxynojirimycinis (2R,3R,4R,5S)-2-(hydroxymethyl) piperidine-3,4,5-triol, which is the nature active components existingin mulberryresources including leaves, stems, roots and silkworm larva, silkworm chrysalis, etc.The 1-deoxynojirimycin is a polyhydroxylated piperidine alkaloid, which was first found in Streptomyces as an antibiotic. Then the Japanese researchers isolated it from the mulberry root. 1-DNJ can inhibit postprandial hyperglycemia by suppressing intestinal alpha glucosidase. Therefore, 1-DNJ is often used to treat treating diabetes and complicating disease and to prevent obesity and weight-related disorders. With the development of the researches, 1-deoxynojirimycin and its derivtiv was discovered to possess anti-hyperglycemic, anti-virus, anti-tumor functions and so on. Therefore,based on our current studythe existing knowledge on source, technique preparation process, pharmacokinetics, bioactivties,and in silico target fishing of 1-DNJ were summarized, so that the researchers may use it to explore future perspective of research on 1-DNJ.
9.Zexie Decoction regulates Akt/TFEB signaling pathway to promote lipophagy in hepatocytes.
Meng-Yao WANG ; Er-Wen LI ; Gai GAO ; Zhong-Xue FU ; Xiao-Wei ZHANG ; Hui WANG ; Pan WANG ; Zhen-Qiang ZHANG ; Jiang-Yan XU ; Zhi-Shen XIE
China Journal of Chinese Materia Medica 2022;47(22):6183-6190
Taking lipophagy as the breakthrough point, we explored the mechanism of Zexie Decoction(ZXD) in improving lipid metabolism in the hepatocyte model induced by palmitic acid(PA) and in the animal model induced by high-fat diet(HFD) on the basis of protein kinase B(Akt)/transcription factor EB(TFEB) signaling pathway. Co-localization was carried out for the microtubule-associated protein light chain 3(LC3) plasmid labeled with green fluorescent protein(GFP) and lipid droplets(LDs), and immunofluorescence co-localization for liver LC3 of HFD mice and perilipin 2(PLIN2). The results showed that ZXD up-regulated the expression of LC3, reduced lipid accumulation in hepatocytes, and increased the co-localization of LC3 and LDs, thereby activating lipo-phagy. Western blot results confirmed that ZXD increased autophagy-related protein LC3Ⅱ/LC3Ⅰ transformation ratio and lysosome-associated membrane protein 2(LAMP2) in vivo and in vitro and promoted the degradation of sequestosome-1(SQSTM1/p62)(P<0.05). The results above jointly explained that ZXD regulated lipophagy. Furthermore, ZXD activated TFEB expression(P<0.05) and reversed the PA-and HFD-induced decrease of TFEB nuclear localization in hepatocytes(P<0.05). Meanwhile, ZXD activated liver TFEB to up-regulate the expression of the targets Lamp2, Lc3 B, Bcl2, and Atg5(P<0.05). Additionally, ZXD down-regulated the protein level of p-Akt upstream of TFEB in vivo and in vitro. In conclusion, ZXD may promote lipophagy by regulating the Akt/TFEB pathway.
Animals
;
Mice
;
Autophagy/drug effects*
;
Hepatocytes/metabolism*
;
Microtubule-Associated Proteins/metabolism*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Signal Transduction
;
Drugs, Chinese Herbal/pharmacology*
10.2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs.
Hao Zhe SHI ; Ping MA ; Feng Ying GAO ; Gong Lie CHEN ; Yu Hui WANG ; Xun De XIAN ; Er Dan DONG
Chinese Journal of Cardiology 2020;48(7):532-538
Angiotensin Receptor Antagonists
;
Angiotensin-Converting Enzyme 2
;
Betacoronavirus
;
COVID-19
;
Cardiovascular Agents/pharmacology*
;
Cardiovascular Diseases
;
Coronavirus Infections/physiopathology*
;
Humans
;
Pandemics
;
Peptidyl-Dipeptidase A/physiology*
;
Pneumonia, Viral/physiopathology*
;
SARS-CoV-2